In the latest close session, Astera Labs, Inc. (ALAB) was down 8.74% at $144.67. The stock trailed the S&P 500, which registered a daily loss of 0.51%. Meanwhile, the Dow gained 0.53%, and the Nasdaq, a tech-heavy index, lost 1.51%. Shares of the company have depreciated by 1.55% over the course of the past month, underperforming the Computer and Technology sector's loss of 0.27%, and the S&P 500'...
In the latest close session, Astera Labs, Inc. (ALAB) was down 8.74% at $144.67. The stock trailed the S&P 500, which registered a daily loss of 0.51%. Meanwhile, the Dow gained 0.53%, and the Nasdaq, a tech-heavy index, lost 1.51%. Shares of the company have depreciated by 1.55% over the course of the past month, underperforming the Computer and Technology sector's loss of 0.27%, and the S&P 500's gain of 0.93%. The investment community will be closely monitoring the performance of Astera Labs, Inc. in its forthcoming earnings report. The company is scheduled to release its earnings on February 10, 2026. In that report, analysts expect Astera Labs, Inc. to post earnings of $0.51 per share. This would mark year-over-year growth of 37.84%. In the meantime, our current consensus estimate forecasts the revenue to be $249.79 million, indicating a 77.03% growth compared to the corresponding quarter of the prior year. For the full year, the Zacks Consensus Estimates are projecting earnings of $1.78 per share and revenue of $831.69 million, which would represent changes of +111.9% and 0%, respectively, from the prior year. Investors should also note any recent changes to analyst estimates for Astera Labs, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. As ...
In the latest close session, Astera Labs, Inc. (ALAB) was down 8.74% at $144.67. The stock trailed the S&P 500, which registered a daily loss of 0.51%. Meanwhile, the Dow gained 0.53%, and the Nasdaq, a tech-heavy index, lost 1.51%. Shares of the company have depreciated by 1.55% over the course of the past month, underperforming the Computer and Technology sector's loss of 0.27%, and the S&P 500'...
In the latest close session, Astera Labs, Inc. (ALAB) was down 8.74% at $144.67. The stock trailed the S&P 500, which registered a daily loss of 0.51%. Meanwhile, the Dow gained 0.53%, and the Nasdaq, a tech-heavy index, lost 1.51%. Shares of the company have depreciated by 1.55% over the course of the past month, underperforming the Computer and Technology sector's loss of 0.27%, and the S&P 500's gain of 0.93%. The investment community will be closely monitoring the performance of Astera Labs, Inc. in its forthcoming earnings report. The company is scheduled to release its earnings on February 10, 2026. In that report, analysts expect Astera Labs, Inc. to post earnings of $0.51 per share. This would mark year-over-year growth of 37.84%. In the meantime, our current consensus estimate forecasts the revenue to be $249.79 million, indicating a 77.03% growth compared to the corresponding quarter of the prior year. For the full year, the Zacks Consensus Estimates are projecting earnings of $1.78 per share and revenue of $831.69 million, which would represent changes of +111.9% and 0%, respectively, from the prior year. Investors should also note any recent changes to analyst estimates for Astera Labs, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. As ...
Declines in tech stocks intensified Wednesday, spreading from software into semiconductor shares and other companies linked to the infrastructure buildout for artificial intelligence. The Nasdaq composite posted consecutive 1% declines for the first time since April’s tariff chaos. The moves rattled investors already unnerved by the recent pullback in software stocks that accelerated after the sta...
Declines in tech stocks intensified Wednesday, spreading from software into semiconductor shares and other companies linked to the infrastructure buildout for artificial intelligence. The Nasdaq composite posted consecutive 1% declines for the first time since April’s tariff chaos. The moves rattled investors already unnerved by the recent pullback in software stocks that accelerated after the startup Anthropic unveiled a suite of new tools, which can perform industry-specific functions like reviewing legal contracts.
In the latest close session, Astera Labs, Inc. (ALAB) was down 8.74% at $144.67. The stock trailed the S&P 500, which registered a daily loss of 0.51%. Meanwhile, the Dow gained 0.53%, and the Nasdaq, a tech-heavy index, lost 1.51%. Shares of the company have depreciated by 1.55% over the course of the past month, underperforming the Computer and Technology sector's loss of 0.27%, and the S&P 500'...
In the latest close session, Astera Labs, Inc. (ALAB) was down 8.74% at $144.67. The stock trailed the S&P 500, which registered a daily loss of 0.51%. Meanwhile, the Dow gained 0.53%, and the Nasdaq, a tech-heavy index, lost 1.51%. Shares of the company have depreciated by 1.55% over the course of the past month, underperforming the Computer and Technology sector's loss of 0.27%, and the S&P 500's gain of 0.93%. The investment community will be closely monitoring the performance of Astera Labs, Inc. in its forthcoming earnings report. The company is scheduled to release its earnings on February 10, 2026. In that report, analysts expect Astera Labs, Inc. to post earnings of $0.51 per share. This would mark year-over-year growth of 37.84%. In the meantime, our current consensus estimate forecasts the revenue to be $249.79 million, indicating a 77.03% growth compared to the corresponding quarter of the prior year. For the full year, the Zacks Consensus Estimates are projecting earnings of $1.78 per share and revenue of $831.69 million, which would represent changes of +111.9% and 0%, respectively, from the prior year. Investors should also note any recent changes to analyst estimates for Astera Labs, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. As ...
Singer LaMonte McLemore has died. He was a founding member of the 5th Dimension, a vocal group whose smooth pop and soul sounds with a touch of psychedelia brought them big hits in the 1960s and 70s. McLemore died on Tuesday aged 90 at his home in Las Vegas, surrounded by his family, his representative Jeremy Westby said in a statement. He died of natural causes after having a stroke. The 5th Dime...
Singer LaMonte McLemore has died. He was a founding member of the 5th Dimension, a vocal group whose smooth pop and soul sounds with a touch of psychedelia brought them big hits in the 1960s and 70s. McLemore died on Tuesday aged 90 at his home in Las Vegas, surrounded by his family, his representative Jeremy Westby said in a statement. He died of natural causes after having a stroke. The 5th Dimension had broad crossover success and won six Grammy Awards including record of the year twice, for 1967’s Up, Up and Away and 1969’s Aquarius/Let the Sunshine In. Both songs were also top 10 pop hits, with Aquarius/Let the Sunshine In, a mashup of songs from the musical Hair, spending six weeks at No 1. McLemore had a parallel career as a sports and celebrity photographer whose pictures appeared in magazines including Jet. The St Louis-born McLemore had served in the US navy, where he worked as an aerial photographer. He played baseball in the Los Angeles Dodgers’ farm system and settled in southern California, where he began making use of his warm bass voice and skill with a camera. He sang in a jazz ensemble, the Hi-Fi’s, with future 5th Dimension bandmate Marilyn McCoo. The group opened for Ray Charles in 1963, but broke up the following year. Later, McLemore, McCoo and two of his childhood friends from St Louis, Billy Davis Jr and Ronald Towson, along with schoolteacher Florence LaRue, formed a singing group called the Versatiles in 1965, and signed to singer Johnny Rivers’ new label, Soul City Records. Rivers told the group, his first signees, that their name wasn’t current enough. Towson came up with the 5th Dimension, a name that would echo the sprinkling of psychedelia and hippy culture the group embraced. Their breakthrough hit came in 1967 with the Mamas & the Papas’ song Go Where You Wanna Go. That same year they released the Jimmy Webb-penned Up, Up and Away, which would go to No 7 on the Billboard Hot 100. The song would later win four Grammys: record of the y...
Generous dividends can help you build wealth in the long run. At the same time, overly generous dividend yields may be a sign of deeply rooted financial struggles. The Dogs of the Dow investing strategy relies on the business quality requirements of the Dow Jones Industrial Average (DJINDICES: ^DJI) If one of the 30 mighty Dow stocks is down on its luck, sending share prices lower and the effectiv...
Generous dividends can help you build wealth in the long run. At the same time, overly generous dividend yields may be a sign of deeply rooted financial struggles. The Dogs of the Dow investing strategy relies on the business quality requirements of the Dow Jones Industrial Average (DJINDICES: ^DJI) If one of the 30 mighty Dow stocks is down on its luck, sending share prices lower and the effective dividend yield higher, that's surely a temporary issue. Buy while the dividend is high and wait for the Dow component to get over that speed bump. But what if you apply the same philosophy to a much broader universe of stocks? There are 1,730 stocks on the Nasdaq (NASDAQ: NDAQ) stock exchange with a market cap of $200 million or more. Are the top-yielding dividend policies in this large group green flags on fantastic buying opportunities -- or red flags marking companies in deep trouble? Let's find out. Here are the three richest dividend yields on the Nasdaq today, each with a quick analysis to separate the buying opportunities from the red-flag danger zones. DouYu International: 62.9% dividend yield Live-streaming e-sports specialist DouYu (NASDAQ: DOYU) is a special case. The China-based company isn't in the habit of paying quarterly dividends. But it issued a special dividend on Sept. 3, amounting to $9.76 per American depositary share (ADS). That amounts to 52% of DouYu's price per ADS on the eve of that disbursal. The company took this extraordinary action to give shareholders something to celebrate despite heavy economic pressure on DouYu's business operations. Revenue has trended downward for nearly three years now, and the bottom-line earnings are printed in red ink. DouYu's incredible dividend yield is a unique one-time item, not a dependable payout policy. You shouldn't expect the company to maintain this downright unreasonable yield. Instead, you should wonder why DouYu felt compelled to share so much cash with stockholders in 2024. The ADS enjoyed a brief per...
Earnings Call Insights: Accuray Incorporated (ARAY) Q2 2026 Management View Steve LaNeve, President, CEO & Director, opened the call highlighting a comprehensive transformation plan to "sharpen accountability, tighten cost control and accelerate execution while positioning Accuray for sustained profitable growth." LaNeve emphasized actions including rightsizing the cost structure, realigning the o...
Earnings Call Insights: Accuray Incorporated (ARAY) Q2 2026 Management View Steve LaNeve, President, CEO & Director, opened the call highlighting a comprehensive transformation plan to "sharpen accountability, tighten cost control and accelerate execution while positioning Accuray for sustained profitable growth." LaNeve emphasized actions including rightsizing the cost structure, realigning the organization, and centralizing functions, with the goal of improving operating profitability by approximately $25 million annually and targeting about $12 million in benefit for fiscal 2026. LaNeve explained that the transformation plan involves a workforce reduction of about 15% and is expected to result in approximately $10 million in restructuring charges during fiscal quarters two through four. The company is expanding and diversifying its service portfolio with a "solutions-oriented offering that increases customer uptime, enhances system performance and drives higher-margin recurring revenue." Additional initiatives include optimizing distributor partnerships, implementing systems to ensure proper compensation for services, and revisiting pricing strategies across products and services. LaNeve stated, "Our revised guidance on the revenue will be in the range of $440 million to $450 million, with adjusted EBITDA guidance of $22 million to $25 million. This compares to our previous guidance of $471 million to $485 million of revenue and $31 million to $35 million of adjusted EBITDA." The company is seeking a new global Chief Commercial Officer to support its long-term objectives. CFO Ali Pervaiz reported, "Net revenue for the quarter was $102.2 million, which was down 12% versus the prior year and down 13% on a constant currency basis. Product revenue for the second quarter was $45 million, down 26% overall... our service business was quite resilient... at $57.2 million in revenue, up 4% from the prior year." Outlook The company lowered its fiscal 2026 revenue guidance t...
Key Points Sterling Investment Management, LLC initiated a 39,433-share position in VBIL, with an estimated transaction value of $2.97 million based on quarterly average pricing. The quarter-end value of the VBIL stake increased by $2.97 million, reflecting both new share purchases and price movement over the period. This position represents 1.69% of 13F reportable assets under management (AUM). P...
Key Points Sterling Investment Management, LLC initiated a 39,433-share position in VBIL, with an estimated transaction value of $2.97 million based on quarterly average pricing. The quarter-end value of the VBIL stake increased by $2.97 million, reflecting both new share purchases and price movement over the period. This position represents 1.69% of 13F reportable assets under management (AUM). Post-filing, the fund holds 39,433 VBIL shares valued at $2.97 million. VBIL is not among the fund’s top five holdings after the trade, placing it outside the most significant positions by size. 10 stocks we like better than Vanguard Institutional Index Funds - Vanguard 0-3 Month Treasury Bill ETF › On Feb. 2, 2026, Sterling Investment Management, LLC disclosed a new position in Vanguard Institutional Index Funds - Vanguard 0-3 Month Treasury Bill ETF (NASDAQ:VBIL), acquiring 39,433 shares in an estimated $2.97 million trade based on quarterly average pricing. What happened According to an SEC filing dated Feb. 2, 2026, Sterling Investment Management, LLC established a new position in Vanguard Institutional Index Funds - Vanguard 0-3 Month Treasury Bill ETF, acquiring 39,433 shares during the fourth quarter of 2025. The transaction is estimated at $2.97 million based on the average price over the quarter. The quarter-end value of the position also stands at $2.97 million, reflecting both the purchase and subsequent price shifts. What else to know This was a new position for the fund, representing 1.69% of its 13F reportable assets under management as of Dec. 31, 2025. Top holdings after the filing: NASDAQ: VMBS: $15.3 million (8.7% of AUM) NYSE: BRK.B: $15.0 million (8.5% of AUM) NYSEMKT: GLD: $13.5 million (7.7% of AUM) NYSE: GE: $7.9 million (4.5% of AUM) NASDAQ: GOOG: $7.5 million (4.3% of AUM) As of Feb. 2, 2026, VBIL shares were priced at $75.43. VBIL’s one-year total return was 4.0%, underperforming the S&P 500 by 12.4 percentage points. The fund’s annualized dividend ...
Oil fell for the first time in three days after Iran confirmed it would hold negotiations with the US, easing the immediate risk of military strikes against the OPEC producer. West Texas Intermediate slipped toward $64 a barrel, after adding 4.8% over the prior two sessions. Brent settled near $69 on Wednesday. Iranian Foreign Minister Abbas Araghchi confirmed in a social media post that the negot...
Oil fell for the first time in three days after Iran confirmed it would hold negotiations with the US, easing the immediate risk of military strikes against the OPEC producer. West Texas Intermediate slipped toward $64 a barrel, after adding 4.8% over the prior two sessions. Brent settled near $69 on Wednesday. Iranian Foreign Minister Abbas Araghchi confirmed in a social media post that the negotiations will be held in Oman on Friday, clarifying the location of the encounter. Differing positions over the parameters of the talks, however, mean it is still unclear whether the two sides can realistically bridge major differences at a time of heightened tensions in the region, which supplies about a third of the world’s crude. That has reinserted a risk premium in oil prices, which have rebounded this year after slumping in the second half of 2025 on signs of a growing global glut. To get Bloomberg’s Energy Daily newsletter in your inbox, click here . WTI for March delivery fell 1.4% to $ 64.20 a barrel at 7:11 a.m. in Singapore. Brent for April settlement closed 3.2% higher at $ 69.46 a barrel on Wednesday.
PhonlamaiPhoto/iStock via Getty Images Back in October of last year, I initiated coverage on Intuitive Surgical, Inc. ( ISRG ). As stated back then, the company is at a very exciting intersection of robotics and healthcare. With this combination of future potential and a valuation that I deemed to be favorable, I believed a buy rating was appropriate. While there were gains after the publication o...
PhonlamaiPhoto/iStock via Getty Images Back in October of last year, I initiated coverage on Intuitive Surgical, Inc. ( ISRG ). As stated back then, the company is at a very exciting intersection of robotics and healthcare. With this combination of future potential and a valuation that I deemed to be favorable, I believed a buy rating was appropriate. While there were gains after the publication of my article, the stock has recently experienced notable weakness. With the company having reported their 2025 Q4 results in late January, today I'll be providing a needed update to see if this dip is something to worry about or whether it is in fact a buying opportunity. Seeking Alpha Below, it is shown that Q4 was generally a mixed quarter for the company. While the outlook for 2026 is also soft, in their earnings call they described an unfavorable environment. These headwinds obviously won't last forever. Furthermore, with the company having their Da Vinci 5 system cleared for some cardiac procedures by the FDA just recently, there are signs that long-term opportunities are growing. Therefore, the valuation that's near multiyear lows shows that this is a chance to buy the dip. The Company Has Come a Long Way Intuitive Surgical Healthcare Conference 2026 Before we get into their Q4 results specifically, it is important to recognize that the company has come a long way both in terms of total patients served and the expansion of their business geographically. You can see above that through 2025, the total cumulative number of patients has surpassed 20.4 million as an indication that their impact on surgery worldwide is very noteworthy. Furthermore, while the company has been around for quite some time, it really has taken until recent years for their business to really take off, and so it seems momentum is on their side right now. Also shown above are three pie charts that show that the company's presence outside of the U.S. has continued to increase. That's an indication t...
Logo of jester cap with thought bubble. Image source: The Motley Fool. DATE Feb. 4, 2026 at 4:45 p.m. ET CALL PARTICIPANTS President and Chief Executive Officer — Cristiano Amon Chief Financial Officer — Akash Palkhiwala Senior Vice President, Investor Relations — Mauricio Lopez-Hodoyan President, Technology Licensing — Alex Rogers TAKEAWAYS Total Revenue -- $12.3 billion, a quarterly record, dire...
Logo of jester cap with thought bubble. Image source: The Motley Fool. DATE Feb. 4, 2026 at 4:45 p.m. ET CALL PARTICIPANTS President and Chief Executive Officer — Cristiano Amon Chief Financial Officer — Akash Palkhiwala Senior Vice President, Investor Relations — Mauricio Lopez-Hodoyan President, Technology Licensing — Alex Rogers TAKEAWAYS Total Revenue -- $12.3 billion, a quarterly record, directly attributed to high flagship handset demand. Non-GAAP EPS -- $3.50, which reached the upper end of the range provided in previous guidance. QCT Revenue -- $10.6 billion, with notable strength attributed to flagship handset launches and records in automotive and IoT. QCT Handset Revenue -- $7.8 billion, supported by recently launched flagship smartphones and above-expected premium segment sell-through. QCT IoT Revenue -- $1.7 billion, up 9% year over year, driven by consumer and networking product demand. QCT Automotive Revenue -- $1.1 billion, representing 15% year-over-year growth on stronger Snapdragon digital chassis demand. Company-Wide Shareholder Returns -- $3.6 billion returned, composed of $2.6 billion in stock repurchases and $949 million in dividends. QCT EBT Margin -- 31% for the period, surpassing the long-term target of 30%. QTL Revenue -- $1.6 billion with an EBITDA margin of 77%, both at the high end of internal guidance. Flagship Smartphone Market Share -- Management expects to maintain an approximately 75% share in Samsung’s upcoming premium devices. Q2 Revenue Guidance -- $10.2 billion to $11 billion, with non-GAAP EPS forecast at $2.45 to $2.65. Q2 QCT Guidance -- Revenue expected between $8.8 billion and $9.4 billion; EBITDA margins guided at 26%-28%. Q2 QTL Guidance -- Revenue forecasted between $1.2 billion and $1.4 billion, with EBT margins of 68%-72% reflecting sequential normal trends. Q2 QCT Handset Revenue Guidance -- Approximately $6 billion, reflecting anticipated impact from industry-wide constrained memory supply. Q2 QCT IoT Revenue Outloo...
Image source: The Motley Fool. Wednesday, Feb. 4, 2026 at 5 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Rajesh Vashist Chief Financial Officer — Beth Howe Need a quote from a Motley Fool analyst? Email [email protected] TAKEAWAYS Revenue -- $113.3 million for the quarter, up 66% year over year and 36% sequentially from fiscal Q3 2025 (period ended Dec. 31, 2025), marking the first time SiT...
Image source: The Motley Fool. Wednesday, Feb. 4, 2026 at 5 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Rajesh Vashist Chief Financial Officer — Beth Howe Need a quote from a Motley Fool analyst? Email [email protected] TAKEAWAYS Revenue -- $113.3 million for the quarter, up 66% year over year and 36% sequentially from fiscal Q3 2025 (period ended Dec. 31, 2025), marking the first time SiTime Corporation SITM 0.99% ) -- $113.3 million for the quarter, up 66% year over year and 36% sequentially from fiscal Q3 2025 (period ended Dec. 31, 2025), marking the first time Non-GAAP EPS -- $1.53, more than triple the $0.48 reported in fiscal Q4 2024. -- $1.53, more than triple the $0.48 reported in fiscal Q4 2024. Gross margin -- 61.2% for the quarter, a 240 basis point improvement year over year, ending above the 60% exit target. -- 61.2% for the quarter, a 240 basis point improvement year over year, ending above the 60% exit target. Comms enterprise data center revenue -- $64.6 million, or 57% of total revenue, representing 160% year-over-year growth and the seventh consecutive quarter above 100% growth. -- $64.6 million, or 57% of total revenue, representing 160% year-over-year growth and the seventh consecutive quarter above 100% growth. Book-to-bill ratio -- Over 1.5 at quarter-end, with management noting, "excellent visibility for the year." -- Over 1.5 at quarter-end, with management noting, "excellent visibility for the year." Inventory -- Ended at $81.7 million, down from $86.7 million in fiscal Q3, with inventory levels stated as in line with company targets. -- Ended at $81.7 million, down from $86.7 million in fiscal Q3, with inventory levels stated as in line with company targets. Operating income -- $34 million for the quarter, a $26 million increase year over year, reflecting cost leverage as revenue scaled. -- $34 million for the quarter, a $26 million increase year over year, reflecting cost leverage as revenue scaled. Cash flow from operations -- $2...
The Illinois governor, JB Pritzker, has announced that his state will join the World Health Organization’s Global Outbreak Alert and Response Network (GOARN), following Donald Trump’s decision to withdraw the US from the global body in 2025. Pritzker, a Democrat, made the announcement on Tuesday, confirming that Illinois will become part of the coordinated international network dedicated to monito...
The Illinois governor, JB Pritzker, has announced that his state will join the World Health Organization’s Global Outbreak Alert and Response Network (GOARN), following Donald Trump’s decision to withdraw the US from the global body in 2025. Pritzker, a Democrat, made the announcement on Tuesday, confirming that Illinois will become part of the coordinated international network dedicated to monitoring and responding to global disease outbreaks. “By withdrawing from the World Health Organization, Donald Trump has undermined science and weakened our nation’s ability to detect and respond to global health threats. I refuse to sit idly by and let that happen,” Pritzker said. He added: “By joining the World Health Organization’s coordinated network, GOARN, we are ensuring that our public health leaders – and the public – have the information, expertise and partnerships they need to protect the people of our state. Across our state and alongside valued partners around the world, Illinois will continue to put science, preparedness and people first.” Illinois’ lieutenant governor, Juliana Stratton, echoed the governor’s remarks, saying: “We will always choose the health of our people over political grandstanding or misinformation, and we will remain focused on what keeps families and communities safe.” Through its membership in GOARN, Illinois will gain direct access to global early-warning alerts and outbreak intelligence, as well as opportunities for technical collaboration and surge support during major public health emergencies. The state will also participate in international training programs, exercises and best-practice exchanges, Pritzker’s office said. Illinois’s move comes after Trump made the decision to withdraw the US from the World Health Organization (WHO) upon retaking office last year. The US had been the WHO’s largest donor, accounting for about 18% of its total funding. Its departure led to the loss of nearly a quarter of the WHO’s workforce – about 2,000...
Michael Derrer Fuchs/iStock Editorial via Getty Images Introduction Shares in UBS Group ( UBS ) are down on Q4 2025 earnings, which reflect the ongoing impact of the Credit Suisse integration. The bank also unveiled an ambitious 18% return on CET1 [RoCET1] profitability target for 2028, likely indicating that reported earnings should increase materially in 2026-2028. Even so, I maintain a Hold rat...
Michael Derrer Fuchs/iStock Editorial via Getty Images Introduction Shares in UBS Group ( UBS ) are down on Q4 2025 earnings, which reflect the ongoing impact of the Credit Suisse integration. The bank also unveiled an ambitious 18% return on CET1 [RoCET1] profitability target for 2028, likely indicating that reported earnings should increase materially in 2026-2028. Even so, I maintain a Hold rating on UBS, driven by: Limited near-term catalysts as the shares trade at a circa 50% trailing P/E premium versus European banking peers. Incremental reported profitability improvements, likely indicating that the premium should shrink to only 6% by 2028. Execution risks to reaching the 2028 return aspiration, leaving little room for error in light of the 68% tangible book premium. The bank's latest Q4 2025 results presentation is available here . Let's now dive into UBS's recent financials before exploring its near-term 2026 plans and 2028 aspirations. I then elaborate on UBS's valuation relative to peers, ultimately confirming a Hold rating in line with my previous coverage . Q4 2025 Results Overview UBS reported EPS of $0.37/share, up 61% Y/Y. The surge came as the bank benefited from lower operating expenses and a benign risk environment, while revenue increased thanks to solid performance in the Global Wealth Management, Asset Management, and Investment Bank segments, only partially offset by weakness in Swiss Personal & Corporate Banking. Tangible book value stood at $26.93/share, up 1.5% Q/Q. The return on tangible equity [ROTE] was modest at only 5.8%, albeit a 1.9% improvement Y/Y. The low reported returns are due to the continuing impact of the Credit Suisse integration. Excluding these effects, non-GAAP underlying ROTE stood at 10.5%. UBS remains well-capitalized, with a CET1 ratio of 14.4% at the end of 2025, up 0.13% Y/Y. This allowed the bank to start another $3 billion share buyback. All in all, I think UBS's performance was quite robust in Q4 2025, although ...
A rotation out of software stocks showed little signs of a retreat Wednesday as investors worried about business risks posed by better AI tools. Sarah Hunt, Chief Market Strategist at Alpine Saxon Woods, joins Bloomberg Businessweek Daily to discuss, saying that while it's legitimate, broader AI fear "feeds on itself." Hunt also says that the "huge ecosystems" around software stocks can serve as a...
A rotation out of software stocks showed little signs of a retreat Wednesday as investors worried about business risks posed by better AI tools. Sarah Hunt, Chief Market Strategist at Alpine Saxon Woods, joins Bloomberg Businessweek Daily to discuss, saying that while it's legitimate, broader AI fear "feeds on itself." Hunt also says that the "huge ecosystems" around software stocks can serve as a cushion for any worry. She speaks with Carol Massar and Tim Stenovec. (Source: Bloomberg)